Microbot Medical (MBOT) Q2 2024 earnings summary

Executive summary

• Focused on developing the LIBERTY® Endovascular Robotic Surgical System, targeting minimally invasive surgery markets.

• Achieved FDA IDE approval in June 2024 to commence pivotal human clinical trials; expects 510(k) clearance in H1 2025.

• No revenues generated to date; operations funded by equity, grants, and convertible debt.

• Ongoing military conflict in Israel poses operational risks but has not yet materially impacted business.

Financial highlights

• Net loss for Q2 2024 was $2.47 million, compared to $2.29 million in Q2 2023; six-month net loss was $4.84 million, down from $5.14 million year-over-year.

• Operating loss for the six months ended June 30, 2024 was $4.90 million, compared to $5.24 million in 2023.

• Cash, cash equivalents, and marketable securities totaled $6.46 million as of June 30, 2024.

• Net cash used in operating activities for the first half of 2024 was $4.38 million, down from $5.06 million in the prior year.

• Shareholders’ equity increased to $6.06 million as of June 30, 2024, from $4.50 million at year-end 2023.

Outlook and guidance

• Anticipates continued net losses as R&D and regulatory activities progress.

• Expects 510(k) FDA clearance for LIBERTY® in H1 2025 and CE Mark approval in H2 2026, but timelines are subject to regulatory and operational risks.

• Management believes current funds are sufficient for less than one year; substantial doubt exists about ability to continue as a going concern without additional capital.